Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PROCEPT BioRobotics
The company is selling 6,556,000 shares at $25 a share to support the commercialization of its AquaBeam robotic system for minimally invasive treatment of benign prostatic hyperplasia.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.
The US Medicare agency is allowing more device procedures to be conducted at outpatient hospitals and ambulatory surgical centers (ASC), while approving several new devices for passthrough payments for three years under its Outpatient Prospective Payment System and ASC payment system final rule for 2020, released on 1 November.
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were signed in March and April 2019.
Surgical Equipment & Devices
- Minimally or Less Invasive
Diagnostic Imaging Equipment & Supplies
- Surgical Equipment & Devices